Is there a Bearish outlook for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) this week?

May 18, 2018 - By Clifton Ray

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Coverage

Among 2 analysts covering Sunesis Pharma (NASDAQ:SNSS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sunesis Pharma had 4 analyst reports since November 20, 2017 according to SRatingsIntel. The rating was initiated by Oppenheimer with “Buy” on Monday, November 20. The stock has “Market Perform” rating by Wells Fargo on Tuesday, December 5. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has “Buy” rating given on Monday, December 11 by Wells Fargo. The stock has “Buy” rating by Oppenheimer on Thursday, December 14. Below is a list of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) latest ratings and price target changes.

14/12/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
11/12/2017 Broker: Wells Fargo Rating: Buy Upgrade
05/12/2017 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
20/11/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate

The stock increased 1.49% or $0.04 during the last trading session, reaching $2.73. About 56,382 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has declined 37.14% since May 18, 2017 and is downtrending. It has underperformed by 48.69% the S&P500.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $93.83 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.

Another recent and important Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) news was published by Seekingalpha.com which published an article titled: “Sunesis Pharmaceuticals’ (SNSS) Management on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.